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Introduction {#sec001}
============

According to computerized tomography (CT) studies, COVID-19 pneumonia typically begins with subpleural ground glass opacities with progressive extension \[[@pone.0236312.ref001]\]. Lung ultrasound is well suited to this interstitial, subpleural involvement, and it is now broadly used in intensive care units (ICUs) \[[@pone.0236312.ref002]\]. Typical lung ultrasound of COVID-19 pneumonia reveals a pattern of B-lines (i.e. comet-tail artifacts perpendicular to the pleural surface), which may spread to the whole pleura in severe patients \[[@pone.0236312.ref003]\]. The extension and severity of lung infiltrates can be described numerically with a reproducible and validated lung ultrasound score (LUSS) \[[@pone.0236312.ref004]\]. However, this score has not been widely and routinely used for ARDS monitoring so far. The typical, "lobar" ARDS pattern is driven by posterior consolidations weakening the diagnostic accuracy of the score \[[@pone.0236312.ref005]\], whereas COVID-19 patients exhibit a different (spatial and temporal) course of disease, with a diffuse and rapidly evolving pattern \[[@pone.0236312.ref001]\]. We hypothesized that LUSS might be useful as a tool to non-invasively monitor the evolution of COVID-19 pneumonia at the bedside. We present here a brief report of our early experience of LUSS use.

Patients and methods {#sec002}
====================

LUSS monitoring was rapidly implemented in the management of our COVID-19 patients with RT-PCR-documented COVID-19 pneumonia, especially when requiring mechanical ventilation. Every practitioner in the unit was trained and LUSS was integrated to the daily routine examination. Junior physicians were trained at the bedside, and were accompanied by a trained investigator until a good interobserver agreement was reached (which required about 4--5 LUSS). The LUSS was evaluated at the bedside, as previously described \[[@pone.0236312.ref004]\]. Briefly, 0--3 points were allocated for each of the 12 pre-determined anatomical regions according to ultrasound pattern: normal = 0, well-defined B-lines = 1, coalescent B-lines = 2, consolidation = 3 (total score ranging from 0 to 36). Lung consolidations (scoring 3) were noted only when thickness (perpendicular from pleura) was greater than 15 mm. Sub-pleural thickening and sub-pleural consolidations (thickness 15 mm or thinner) were graded a score of 2. Continuous variables are expressed as median (interquartile range). The result of each score with the detail of each zone was recorded in a table and kept in the patient medical record, allowing the monitoring from day-to-day. The LUSS was evaluated daily, when possible (depending on workload and available medical staff).

This study was approved by our institutional ethics committee (*Comité d'éthique du CHU de Lyon*) and was conducted in accordance with the 1964 Helsinki declaration and its later amendments. Patients and/or relatives gave informed consent for the collection of clinical data.

Results {#sec003}
=======

We report in [Fig 1](#pone.0236312.g001){ref-type="fig"} the course of LUSS during COVID-19 in 10 consecutive patients admitted in our ICU with moderate to severe ARDS between March 15 and 30^th^. Clinical characteristics of these patients were as follows: age 56 (46--63) years, 80% men, body-mass index 32 (30--33), simplified acute physiology score II 36 (34--38). A total of 109 LUSS were assessed for these patients (with 10.9 distinct LUSS evaluations per patient on average). The LUSS at ICU admission was 22 (15--26), maximum and lowest LUSS were 27 (26--29) and 14 (12--15), respectively. During the study period, 4 patients were successfully weaned from mechanical ventilation (MV). In all of them, LUSS on the day of extubation was all lower than admission LUSS, with a LUSS within 24h of extubation ranging from 13 to 17. Patient \#6 was also extubated but was not considered as weaned from mechanical ventilation as he presented an early post-extubation acute respiratory failure requiring high-intensity non-invasive ventilation. His LUSS on the day of extubation was of 27. LUSS increased inexorably in the patient who died from refractory hypoxemia. In the five patients presenting a ventilator-associated pneumonia (VAP), lung ultrasound monitoring showed an increased LUSS and especially the presence of new lung consolidation. Indeed, such new consolidations (zone-score of 3) were detected in the patients with VAPs in one or two zones (often lateral-inferior or posterior-inferior) which were free of consolidation in the previous ultrasound examinations (zone-score of 0, 1 or 2). VAPs were diagnosed with the usual criteria, and the day of VAP occurrence was defined as the day when positive tracheal aspirate or bronchoalveolar fluid was sampled (all VAP episodes were culture-positive). CT-scans were performed in 7 patients and all showed diffuse ground glass opacities. Four CT-scans also found lung consolidations, which were all detected by ultrasonography.

![Clinical course and lung ultrasound score (LUSS) evolution in 10 COVID-19 patients.\
For each timepoint the numerical LUSS is indicated above the corresponding symbol (blue diamond if ultrasound showed only interstitial infiltrates and red if it also showed at least one lung consolidation). Arrows indicate occurrence of a clinically-diagnosed ventilator-associated pneumonia. Mechanical ventilation-free periods are highlighted in green. Patient \#5 died of refractory hypoxemia. Patient \#6 was extubated on April 7^th^ but was placed under non-invasive ventilation due to post-extubation acute respiratory failure. Patients \#4 and \#9 were discharged alive from intensive care during the study period. NIV: non-invasive ventilation; yo: years-old.](pone.0236312.g001){#pone.0236312.g001}

Discussion {#sec004}
==========

Our early experience with LUSS monitoring indicates potential usefulness for the management of COVID-19 patients with ARDS. First, our results suggest that LUSS could contribute to the early diagnosis of VAPs. Lung ultrasound was previously described as a useful tool for VAP diagnosis \[[@pone.0236312.ref006]\], and it might be well suited in the setting of COVID pandemic, where early and/or non-superinfected cases are typically free of lung consolidations \[[@pone.0236312.ref001]\]. One major limitation of LUSS in this setting is that a zone-score of 3 does not allow to compare the size of an existing consolidation from day-to-day, preventing a more subtle interpretation of this capital information. Second, we observed that all patients successfully weaned from MV had a decreased LUSS. Of note, LUSS was validated as a mechanical ventilation-weaning prediction tool \[[@pone.0236312.ref004]\], even though the cut-off value remains to be determined for COVID-19 patients. In all cases, LUSS should not be interpreted in isolation but rather integrated to the set of usual parameters when considering a therapeutic decision.

Our early experience so far encouraged us to continue and use LUSS in our routine practice for COVID-19 patients, as it seems to accurately reflect disease progression. LUSS evaluation is easy to use and readily available in ICUs throughout the world, and might be a safe, cheap and simple tool to optimize critically ill COVID-19 patients care during the pandemic. Further studies are now needed to determine if LUSS-based interventions can effectively improve the management of COVID-19 patients with ARDS, e.g. by allowing faster MV weaning, earlier detection and treatment of VAPs, or optimizing care efficiency by reducing the need for X-ray and CT exams.
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Dear Dr. Auguste Dargent,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

I have received the comments of the reviewers on your manuscript. The specific comments of the reviewers are included below. Please provide point by point response in your revised manuscript.

Please submit your revised manuscript by due date. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Muhammad Adrish

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. One of the noted authors is a group, COVID-LUS study group.

In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript.

Please also indicate clearly a lead author for this group along with a contact email address.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: N/A

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The article describes monitoring of pneumonia progression in patients with COVID-19 infection using lung ultrasound.

It is well written and interesting.

Lung ultrasound is an established approach for monitoring pulmonary diseases in the ICU. It makes a lot of sense to use this method in this population of COVID-19 infected patients from an infection control perspective. It is a bedside test and can be performed rather quickly. If done by experienced providers, it can save trips to the CT which always comes at a risk of infecting other patients or staff if the patient traveling for the test has a contagious disease.

The provided figure gives a good overview of score development during the hospitalization and puts it in clinical perspective.

My only critique is that it would be very helpful for the reader to have a panel of pictures from a patient prior and post development of VAP to illustrate the described changes as the authors promote this method for earlier diagnosis of VAP in COVID-19 patients. This is particularly important as there is currently debate about the difference of ARDS in patient with COVID-19 amongst themself and compared to the traditional population diagnosed with ARDS.

Reviewer \#2: I do want to congratulate the authors on their work. This is an interesting paper looking at the LUSS score in the management of the COVID 19 patients.

Using of Lung US in well documented in the critical care practice. Use of LUSS score has been used in management of ARDS.

Although study is interesting there are many limitations to study. First the patient number is small to draw any definite conclusions

Second there no clear mythological pattern describe by author , as daily or twice a day LUSS score assessment.

Third: In patient outcomes, it would be ideal to know what was the LUSS score prior to extubation if that is available, as there are studies that have showed correlation between the two. Ref : Caltabeloti F, Monsel A, Arbelot C, Brisson H, Lu Q, Gu WJ, et al. Early fluid loading in acute respiratory distress syndrome with septic shock deteriorates lung aeration without impairing arterial oxygenation: a lung ultrasound observational study. Crit Care 2014;18:R91.

Fourth : The author have showed LUSS score \>1 region with score of 3 and then marked that point as VAP in 5 of their patients , it would be beneficial to know if these ultrasound finding also correlated with clinically diagnosis of VAP.

Fifth: It has been established that score of 3 can have limitations as that if the area consolation is not in taken into account, it can overestimate the lack of aeration and give a high score, I would like if authors could justify if they took this into consideration. Ref: Chiumello D, Mongodi S, Algieri I, Vergani GL, Orlando A, Via G, et al. Assessment of lung aeration and recruitment by CT scan and ultrasound in acute respiratory distress syndrome patients. Crit Care Med 2018;46:1761--1768.

Overall interesting concept and may be clinically useful tool to guide therapy in treatment of this new disease.

Reviewer \#3: General

In this manuscript, Dargent et al describe serial assessments of the Lung Ultrasound Score (LUSS) on 10 consecutive patients admitted to their intensive care unite with moderate to severe ARDS. Multiple scores were available for each patient (average of 10.9 scans per patient on average) and their course of LUSSs were tracked throughout the study. They found that in successfully extubated patients, the LUSS decreased and was lower than at the time of intubation. In a patient who died from refractory hypoxemia the LUSS increased. They suggest that the LUSS accurately reflects disease progression and may help in early VAP diagnosis, mechanical ventilation weaning management, and potentially reduce the need for other imaging.

Overall I was intrigued by the apparent association in lower scores in those who were successfully weaned from mechanical ventilation, but I don't have strong confidence in the validity of this claim given the unknown result of patient \#6 (see below). Whether patient \#6 needed non-invasive ventilation or was re-intubated it was associated with a high LUSS indicating that extubation may have been premature.

Major

A PubMed entry of \"COVID Lung US\" yielded 243 results -- as such, this study has missed the opportunity to be presented as "pioneering" work, and as such a description of 10 patients without the ability to clearly demonstrate added value beyond already available clinical data, and without any statistical testing at all fundamentally limits my enthusiasm.

The short term and variable length of followup is problematic. Figure 1 shows this problem graphically and makes it hard to draw any meaningful conclusions about the observations described.

It's not clear how the results of the LUSS affected care, particularly with the lack of a control group. It's impossible to draw conclusions of benefit from this manuscript.

Patient \#6 was extubated on April 7th with a LUSS of 27, but placed on non-invasive ventilation. It is not mentioned if this patient was re-intubated or not, but if the patient was not I wonder if the group is wrong to which the patient is assigned. If not re-intubated then the patient was breathing spontaneously on non-invasive ventilation and by some would be considered to have been successfully extubated. Was the patient not included in this group because of re-intubation or because the LUSS would not allow a claim of lower LUSS in those successfully extubated because of the LUSS at that time being 27 or because the authors felt that the need for non-invasive ventilation does not meet the criteria of a successful wean from mechanical ventilation?

A claim is made that the LUSS decreased for those patients who were successfully extubated, but I see no statistical analysis of the LUSS to see if there was actually a statistical difference.

Minor

I cannot find the number of sonographers reported who performed the exams. Given the operator dependent nature of ultrasonography there is a potential for issues with inter-observer reliability. This may have led differences in LUSS not due to a change in disease severity, but purely because another sonographer scanned the patient that day.

The method by which the diagnosis of VAP was reached was not outlined in the study or whether the sonographer was blinded to this or if they were the ones making the diagnosis.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Andreas Schmid

Reviewer \#2: No

Reviewer \#3: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: The article describes monitoring of pneumonia progression in patients with COVID-19 infection using lung ultrasound.

It is well written and interesting.

Lung ultrasound is an established approach for monitoring pulmonary diseases in the ICU. It makes a lot of sense to use this method in this population of COVID-19 infected patients from an infection control perspective. It is a bedside test and can be performed rather quickly. If done by experienced providers, it can save trips to the CT which always comes at a risk of infecting other patients or staff if the patient traveling for the test has a contagious disease.

The provided figure gives a good overview of score development during the hospitalization and puts it in clinical perspective.

The authors thank the reviewer for these comments.

My only critique is that it would be very helpful for the reader to have a panel of pictures from a patient prior and post development of VAP to illustrate the described changes as the authors promote this method for earlier diagnosis of VAP in COVID-19 patients. This is particularly important as there is currently debate about the difference of ARDS in patient with COVID-19 amongst themself and compared to the traditional population diagnosed with ARDS.

We thank the reviewer for raising this point. Unfortunately, we did not save specific images for each patient, which would have been a very good illustration of the changes observed in a given patient along time. In all cases of ventilator-acquired pneumonia detected by ultrasonographic monitoring, it was evidenced by the apparition in one or two zones (often lateral or posterior) of a lung consolidation in a zone previously free of consolidation, within a few days' interval. We are not able to show the actual images taken in the same patient, but we added a more precise description of the changes observed when a VAP was diagnosed. We also added details in the methods section as to how the score was recorded zone by zone.

Reviewer \#2: I do want to congratulate the authors on their work. This is an interesting paper looking at the LUSS score in the management of the COVID 19 patients.

Using of Lung US in well documented in the critical care practice. Use of LUSS score has been used in management of ARDS.

Although study is interesting there are many limitations to study. First the patient number is small to draw any definite conclusions

The authors absolutely agree with the reviewer \#2. Our point is to give an overview of the use of this simple tool in the clinical practice during the pandemic. Even with the little number of patients presented here and managed later in our unit, we felt that ultrasound monitoring brought useful insight of the clinical evolution of these complex patients. That is why we wanted to share our experience with an individual, visual overview allowed by the numeric LUS score.

Second there no clear mythological pattern describe by author , as daily or twice a day LUSS score assessment.

The LUS monitoring was implemented as a "real life" monitoring tool. The medical staff available and workload allowed daily monitoring for some periods but this was more difficult at other times (e.g. weekends). We agree that systematic screening with a fixed interval would have been ideal, although difficult to apply in this stressful period. A statement was added to the methods section.

Third: In patient outcomes, it would be ideal to know what was the LUSS score prior to extubation if that is available, as there are studies that have showed correlation between the two. Ref : Caltabeloti F, Monsel A, Arbelot C, Brisson H, Lu Q, Gu WJ, et al. Early fluid loading in acute respiratory distress syndrome with septic shock deteriorates lung aeration without impairing arterial oxygenation: a lung ultrasound observational study. Crit Care 2014;18:R91.

We fully agree with this comment. Indeed mechanical ventilation weaning is one major point where LUSS monitoring could be useful. We added the range of LUS scores of the extubated patients. The individual scores can be visualized on the figure (spontaneous breathing after successful extubation materialized by the green background color).

Fourth : The author have showed LUSS score \>1 region with score of 3 and then marked that point as VAP in 5 of their patients , it would be beneficial to know if these ultrasound finding also correlated with clinically diagnosis of VAP.

Thank you for raising this point. The VAPs indicated by arrows in the figure were clinically diagnosed and treated. The arrow is placed on the day when positive tracheal aspirate or bronchoalveolar fluid was sampled. We made it clear by adding a statement in the legend of the figure and in the results section.

Fifth: It has been established that score of 3 can have limitations as that if the area consolation is not in taken into account, it can overestimate the lack of aeration and give a high score, I would like if authors could justify if they took this into consideration. Ref: Chiumello D, Mongodi S, Algieri I, Vergani GL, Orlando A, Via G, et al. Assessment of lung aeration and recruitment by CT scan and ultrasound in acute respiratory distress syndrome patients. Crit Care Med 2018;46:1761--1768.

We thank the reviewer for this very interesting comment. In the study cited by the reviewer, LUS 3 was not able to discriminate regions in which lung aeration was improved by PEEP, because the score 3 is given regardless of the size of the lung consolidation. This is indeed a major drawback of the LUS score, which was not taken into account in our study. For example, if a different physician is seeing the patient each day, he/she will not know if the consolidation size observed is decreased, increased or stable by just seeing "LUS 3" on the chart. We added a statement in the discussion section.

Overall interesting concept and may be clinically useful tool to guide therapy in treatment of this new disease.

Reviewer \#3: General

In this manuscript, Dargent et al describe serial assessments of the Lung Ultrasound Score (LUSS) on 10 consecutive patients admitted to their intensive care unite with moderate to severe ARDS. Multiple scores were available for each patient (average of 10.9 scans per patient on average) and their course of LUSSs were tracked throughout the study. They found that in successfully extubated patients, the LUSS decreased and was lower than at the time of intubation. In a patient who died from refractory hypoxemia the LUSS increased. They suggest that the LUSS accurately reflects disease progression and may help in early VAP diagnosis, mechanical ventilation weaning management, and potentially reduce the need for other imaging.

Overall I was intrigued by the apparent association in lower scores in those who were successfully weaned from mechanical ventilation, but I don't have strong confidence in the validity of this claim given the unknown result of patient \#6 (see below). Whether patient \#6 needed non-invasive ventilation or was re-intubated it was associated with a high LUSS indicating that extubation may have been premature.

We thank the reviewer for raising this important point. The case of this particular patient is of interest and our description might be incomplete. Patient \#6 was indeed extubated with a LUSS of 26 and presented an acute respiratory failure within 12 hours after extubation, requiring "rescue" non-invasive ventilation and high flow nasal cannula. That is why he is not included in "patients successfully weaned from mechanical ventilation". This is explained in the figure legend. We added a statement in the result section. Furthermore, we modified the figure's legend to make the outcome of this patient more clear.

Major

A PubMed entry of \"COVID Lung US\" yielded 243 results -- as such, this study has missed the opportunity to be presented as "pioneering" work, and as such a description of 10 patients without the ability to clearly demonstrate added value beyond already available clinical data, and without any statistical testing at all fundamentally limits my enthusiasm.

As stated above, we wanted to give a rapid overview of the use of this simple tool in the clinical practice during the pandemic with this case series. Even with the little number of patients presented here and managed later in our unit, we felt that ultrasound monitoring brought useful insight of the clinical evolution of these complex patients. That is why we wanted to share our experience with an individual, visual overview allowed by the numeric LUS score. We agree that due to its small size and observational nature, this study does not allow to draw hard conclusions but rather an indication of its potential as a bedside tool.

The short term and variable length of followup is problematic. Figure 1 shows this problem graphically and makes it hard to draw any meaningful conclusions about the observations described.

The authors thank the reviewer for this comment. We agree that the follow-up length were variable, although patients were admitted in a short period of time. We estimated that the clinical courses of our patients were indeed quite different but illustrated well the different complications and turning points where lung ultrasound can bring meaningful insight: clinical deterioration, weaning from mechanical ventilation, nosocomial pneumonia.

We could now extend the follow-up duration for the patients to implement Figure 1, if necessary. However, we fear that it might overcrowd the Figure and make it less legible, without bringing more useful information.

It's not clear how the results of the LUSS affected care, particularly with the lack of a control group. It's impossible to draw conclusions of benefit from this manuscript.

This is absolutely true. We cannot prove that patients benefited from LUSS monitoring. However, we felt that LUSS monitoring definitely improved clinical appraisal of the evolution of COVID-19 lung involvement. COVID-19 ARDS is a complex condition often challenging physicians with complex decisions to make, always based on multiple parameters like PaO2/FiO2, vitals, biomarkers. Our experience modestly suggests that LUSS can be one more parameter to take into account when diagnosing a ventilator acquired pneumonia or deciding whether to extubate a patient.

Patient \#6 was extubated on April 7th with a LUSS of 27, but placed on non-invasive ventilation. It is not mentioned if this patient was re-intubated or not, but if the patient was not I wonder if the group is wrong to which the patient is assigned. If not re-intubated then the patient was breathing spontaneously on non-invasive ventilation and by some would be considered to have been successfully extubated. Was the patient not included in this group because of re-intubation or because the LUSS would not allow a claim of lower LUSS in those successfully extubated because of the LUSS at that time being 27 or because the authors felt that the need for non-invasive ventilation does not meet the criteria of a successful wean from mechanical ventilation?

This case of Patient \#6 was already raised by the reviewer and is indeed interesting. This patient presented a post-extubation acute respiratory failure and required non-invasive ventilation and high flow nasal cannula. However, after a few days his condition improved after a corticosteroid therapy was started and he was not re-intubated. When NIV was finally weaned his LUSS was of 23 (not shown).

This is why we used the term "successfully weaned from mechanical ventilation" in the other patients, rather than "successful extubation". The case of this patient was different because the extubation was not uneventful, and the fact that he had a high LUSS might be an explanation.

A claim is made that the LUSS decreased for those patients who were successfully extubated, but I see no statistical analysis of the LUSS to see if there was actually a statistical difference.

We thank the reviewer for this comment. Given the small size of our patients' sample, we did not perform statistical tests. By "decreased", we meant that each patient's LUSS was lower on the day of extubation as compared to the admission LUSS. We made that point clear in the result section.

Minor

I cannot find the number of sonographers reported who performed the exams. Given the operator dependent nature of ultrasonography there is a potential for issues with inter-observer reliability. This may have led differences in LUSS not due to a change in disease severity, but purely because another sonographer scanned the patient that day.

Thank you for raising this important point. Like we said, the LUSS was implemented in our ICU like a "real life", shared tool. As such, every practitioner in the unit was trained and LUSS was integrated to the daily routine examination (overall by 20 junior and senior physicians). Junior physicians (including residents) were trained at the bedside, and were accompanied by a trained investigator until a good interobserver agreement was reached (about 4-5 LUSS). The reviewer is right about the inter-observer reliability issues that can arise from these multiple sonographers. However, we think it is also a strength of this experience, showing that a decent inter-operator congruence was obtained from such "real life" setting. This strengthens the external validity of this concept. Indeed, intensive care relies, by nature, on the intervention of multiple physicians.

The method by which the diagnosis of VAP was reached was not outlined in the study or whether the sonographer was blinded to this or if they were the ones making the diagnosis.

This point is indeed important and was insufficiently adressed. The VAPs indicated by arrows in the figure were clinically diagnosed and treated. The arrow is placed on the day when positive tracheal aspirate or bronchoalveolar fluid was sampled. The sonographer was not really blinded to the diagnosis of VAP, but it was made independently from the LUSS examination. We added a statement about VAP diagnosis in the legend of the figure and in the results section.
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